Study Identifies Potential Therapeutic Target for Patients With AML
Posted: Thursday, October 14, 2021
For patients with acute myeloid leukemia (AML), increased expression of C-type lectin domain family 2 member B (CLEC2B) may be associated with a poorer prognosis, according to a study published in the Annals of Translational Medicine. These findings may provide a potential therapeutic target for this patient population to improve their prognostic outcomes, suggests Zhenlan Du, MD, of the Chinese PLA General Hospital, Beijing, and colleagues.
A total of 173 patients with AML were recruited for the study. Patients were divided into two clusters and three subclusters based on the similarities in their adaptive immunity-related gene-expression profile. Transcriptional information on 732 genes was collected and analyzed using normalized RNA sequencing.
The study findings did not reveal any significant differences in progression-free survival nor overall survival between patients. In addition, a genetic analysis revealed that 101 genes were significantly associated with peripheral blood blast percentage, and 81 genes were significantly associated with age. Comparison of the two clusters revealed that patients in cluster 1 were typically older and had increased expression of the M5 type, whereas patients in cluster 2 were younger and had an increased expression of the M2 type. Furthermore, assessment of overall prognosis based on each French-American-British subtype revealed that patients who were classified as M3 tended to have the most favorable overall survival and progression-free survival. Moreover, increased expression of CLEC2B was found to be significantly correlated with worse outcomes. Patients from the M2 type had decreased expression of CLEC2B as compared with others.
“Variation in adaptive immunity-related gene expression is significantly associated with clinical characteristics and relapse in patients with AML. Therefore, illuminating the landscape of adaptive immunity-related gene expression can greatly facilitate the understanding of AML,” explained Dr. Du.
Disclosures: For full disclosures of the study authors, visit atm.amegroups.com.